@prefix dcterms: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "incruse ellipta is indicated for the long term once daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd including chronic bronchitis and or emphysema incruse ellipta is an anticholinergic indicated for the long term once daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease copd 1"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "RsoCSjXH1/kY/AIHXPbzRdBvPwYQB+jNv1SRz+E2B2EYPuC14xPVKkne7lV3u6ZwTBHFzq/5HuE2A36KwlbkTi7FyyTaVbilyu2QJiT4yfg52EYy/YnSsDQ2Na4HroGIviVRBmu6ryezuExzxoJD+Lw8ZRAjEZmBOI/oO9JW8XI="; npx:hasSignatureTarget this: . this: dcterms:created "2021-07-03T14:41:07.966+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }